A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT06084936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Study identification
- NCT ID
- NCT06084936
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- Obinutuzumab Drug
- Glofitamab Drug
- Rituximab Drug
- Bendamustine Drug
- Lenalidomide Drug
- Tocilizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2023
- Primary completion
- Aug 30, 2027
- Completion
- Mar 30, 2028
- Last update posted
- Sep 2, 2026
2023 – 2028
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Bates Summit Medical Center | Berkeley | California | 94704 | Withdrawn |
| City of Hope Cancer Center | Duarte | California | 91010 | Recruiting |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | Recruiting |
| University of California Los Angeles (UCLA) - Cancer Care - Santa Monica | Santa Monica | California | 90404-2023 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | Recruiting |
| University of Miami | Coral Gables | Florida | 33146 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Indiana University | Indianapolis | Indiana | 46202 | Withdrawn |
| University of Iowa | Iowa City | Iowa | 52242 | Recruiting |
| University of Iowa Health Care | Waukee | Iowa | 50263 | Recruiting |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | Recruiting |
| St. Luke's Hospital | Chesterfield | Missouri | 63017 | Recruiting |
| Renown Regional Medical Center | Reno | Nevada | 89502 | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | Recruiting |
| Hematology Oncology Associates of Central New York | East Syracuse | New York | 13057 | Recruiting |
| University of Rochester | Rochester | New York | 14642 | Recruiting |
| Stony Brook University Hospital Cancer Center | Stony Brook | New York | 11794 | Recruiting |
| Medical University of S. Carolina | Charleston | South Carolina | 29425 | Withdrawn |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | Withdrawn |
| Renovatio Clinical - El Paso | El Paso | Texas | 79915 | Recruiting |
| Renovatio Clinical | The Woodlands | Texas | 77380 | Recruiting |
| University of Virginia | Charlottesville | Virginia | 22906 | Recruiting |
| West Virginia University | Morgantown | West Virginia | 26506 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06084936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06084936 live on ClinicalTrials.gov.